Twist Bioscience Corp (TWST) Stock Price & Analysis
Twist Bioscience Corp (TWST) rose 0.03% to USD 70.06 as of June 10, 2026 at 00:45 UTC, according to Nexqual real-time market data.
TWST last closed at USD 70.04; the session ranged USD 66.43–73.44 on volume of 1,766,271 shares. Market capitalization is $4.36B, with a 52-week range of USD 23.3–80.5 (NMS). Source: Nexqual, June 10, 2026 at 00:45 UTC.
Key Statistics (as of June 10, 2026 at 00:45 UTC)
| Price | USD 70.06 |
|---|---|
| Change | ▲ 0.03% (up) |
| Previous Close | USD 70.04 |
| Open | USD 71.7 |
| Day Range | USD 66.43 – 73.44 |
| 52-Week Range | USD 23.3 – 80.5 |
| Volume | 1,766,271 shares |
| Market Cap | $4.36B |
| Exchange | NMS |
Technical Analysis (TWST)
Nexqual's technical model rates TWST "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.81 (neutral) |
| vs SMA50 | Above (USD 58.24) |
| MACD | 4.19 (positive) |
Analyst Ratings (TWST)
Wall Street analysts rate TWST "Strong Buy" based on 8 analysts, with a mean price target of USD 64.38 (range USD 36–80), per Nexqual as of June 10, 2026 at 00:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 64.38 |
| High Target | USD 80 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (TWST)
| Next Earnings Date | 2026-08-03 |
|---|---|
| Revenue Estimate | $114.63M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.6 vs est -0.53 ▼ miss |
| 2025-12-31 | USD -0.5 vs est -0.52 ▲ beat |
| 2025-09-30 | USD -0.45 vs est -0.5 ▲ beat |
| 2025-06-30 | USD -0.47 vs est -0.57 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financials & Fundamentals (TWST)
| Total Revenue | $409.48M |
|---|---|
| Revenue Growth (YoY) | +19.30% |
| Gross Margin | +52.07% |
| Operating Margin | -34.92% |
| Profit Margin | -19.85% |
| ROE | -18.16% |
| Debt / Equity | 24.36 |
| Current Ratio | 2.7 |
| Total Cash | $171.67M |
| Total Debt | $110.84M |
| Free Cash Flow | $-58.48M |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Financial Health Score (TWST)
Nexqual rates Twist Bioscience Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:45 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 52%, operating -35% |
| Balance Sheet | Strong — $172M cash vs $111M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$58M, burning cash |
| Efficiency | Critical — ROE -18%, ROA -12.9% |
Ownership (TWST)
| Insider Ownership | +1.26% |
|---|---|
| Institutional Ownership | +123.93% |
| Shares Outstanding | 62.27M |
| Float | 55.41M |
| Short % of Float | +30.69% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
Leadership (TWST)
Twist Bioscience Corp is led by Emily Marine Leproust (age 52), Co-Founder, Board Chair & CEO, per Nexqual as of June 10, 2026 at 00:45 UTC.
| Co-Founder, Board Chair & CEO | Emily Marine Leproust (age 52) |
|---|---|
| President & COO | Patrick John Finn (age 53) |
| Chief Financial Officer | Adam Laponis (age 48) |
| Senior Vice President of Human Resources | Paula Green (age 57) |
| Chief Technology Officer | Siyuan Chen |
Major Backers & Investors (TWST)
Notable institutional backers of Twist Bioscience Corp include ARK Invest, Artisan Partners Limited Partnership, Edgepoint Investment Group Inc., according to Nexqual as of June 10, 2026 at 00:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 18.09% |
| Artisan Partners Limited Partnership | 12.07% |
| Edgepoint Investment Group Inc. | 8.64% |
| William Blair Investment Management, LLC | 8.46% |
| Invesco | 3.49% |
| FMR, LLC | 3.04% |
| Thrivent Mutual Funds-Thrivent Small Cap Stock Fund | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.83% |
| BlackRock | 11.22% |
| State Street | 9.14% |
Source: Nexqual, June 10, 2026 at 00:45 UTC.
From Twist Bioscience Corp's Latest SEC 10-K Filing (filed 2025-11-17)
Key Strengths & Strategy (as disclosed to the SEC)
- The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.
- Our Platform We developed the Twist Bioscience DNA synthesis platform to address the limitations of throughput, scalability, and cost inherent in legacy DNA synthesis methods.
- This growing convergence highlights the power of our integrated platform and reinforces Twist's unique position to serve the full spectrum of innovation in discovery.
- We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost and quicker than our competitors.
Partnerships
- In October 2024, we entered into an agreement with XOMA Royalty under which they paid Twist $15 million cash in exchange for 50% of future milestone and royalty payments from our existing collaborations as of the date of signing.
- Research and development activities are conducted in collaboration with manufacturing activities to help expedite new products from the development phase to manufacturing and to more quickly implement new process technologies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PACB | Pacific Biosciences of Californ | USD 1.37 | ▼ 5.52% |
| TXG | 10x Genomics, Inc. | USD 30.59 | ▼ 1.45% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
| CDNA | CareDx, Inc. | USD 22.75 | ▲ 2.25% |
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:45 UTC. This page is informational and not investment advice.